The Role of Phytoconstituents in Medicinal Plants for Leukemia Therapy: A Thorough Review
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Leukemia is a form of cancer that emanates from the uncontrolled proliferation of undeveloped WBC within the bone marrow, circulatory system, and spleen. There are several kinds of Leukemia, and the type determines the optimal course of treatment and the likelihood of a patient surviving. Traditional leukemia treatment strategies work by focusing on different signaling pathways that are involved in leukemogenesis. The hunt for safer and more effective drugs continues to be one of the most difficult areas of study due to the side effects of this therapy and the problem of drug resistance. Various medications have been utilized to treat leukemia, yet there is a drive to enhance the process by exploring novel therapeutic approaches. Nearly 50% of the medications used in the running globe for treating Leukemia are derived from natural sources, herbal products, their derivatives, and phytoconstituents. Among antileukemic drugs, medicinal plants are a powerful reservoir that provides a dependable source of efficient treatments. Research investigations have looked into the cytotoxic mechanisms responsible for the toxic properties of plant components against cancer cells. Recent developments and significant progress in the treatment of leukemia have resulted from the use of crude drug extracts from several medicinal plants, such as Cephalotaxus harringtonia, which contains phytoconstituents including homoharringtonine and harringtonine. This comprehensive analysis has attempted to draw attention to these trends.
Fields of Study & Subjects
Medicinal Plant Research
Phytochemical Studies and Bioactivities
Natural product bioactivities and synthesis
Publication details
- Journal / source
- Letters in Functional Foods
- Volume
- 03
- Publication date
- 26 March 2026
- Language
- EN